← All trials
NCT04871412
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2021
- Primary completion
- Jul 1, 2023
- Completion date
- Jul 1, 2024
- First posted
- May 4, 2021
- Last posted
- May 4, 2021
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OttawaLead sponsor
- University of OttawaOverall official - principal investigator
- University of OttawaCollaborator
- Lotte & John Hecht Memorial FoundationCollaborator
- The Canadian College of Naturopathic MedicineOverall official - principal investigator
- The Canadian College of Naturopathic MedicineCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.